The American Journal of Managed Care1h
FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
The Lancet13h
Expanding the armamentarium for metabolic dysfunction-associated steatohepatitis
The treatment of metabolic dysfunction-associated steatohepatitis (MASH) has proven challenging, with many compounds failing during development for various reasons. However, with the recent ...
Too Old to Operate20h
Role of CERS1 in Skin Barrier Dysfunction and Staphylococcus aureus in AD
The following is a summary of “CERS1 is a Biomarker of Staphylococcus aureus Abundance and Atopic Dermatitis Severity,” ...
mskcc.org23h
FDA Approves New Drug Combination for ER+, HER2- Breast Cancer
The treatment combines a new drug, inavolisib, with two older breast cancer drugs, fulvestrant (Faslodex ®) and palbociclib (Ibrance ®) . Inavolisib, which targets PIK3CA mutations, appears to be a ...